Group 1 - The company, Beijing Succeeder Technology Co., Ltd., will hold a performance briefing for the first half of 2025 on September 17, 2025, from 15:00 to 17:00 [1][2] - The briefing will be conducted in an online interactive format via the Shanghai Stock Exchange Roadshow Center [2][3] - Investors can submit questions in advance from September 10 to September 16, 2025, and the company will address commonly asked questions during the session [2][3] Group 2 - Key participants in the briefing will include the company's General Manager Wang Hai, Deputy General Manager Ding Zhonghui, and other board members [2] - The contact information for inquiries includes the Board Office's phone number and email address [3]

北京赛科希德科技股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日在 上海证券交易所网站（www.sse.com.cn）披露了《北京赛科希德科技股份有限公司 2025 年半年度报告》，为便于广大投资者更全面深入地了解公司 2025 年上半年度 的经营成果、财务状况、发展理念，公司计划参与 2025 年 09 月 17 日（星期三）1 5:00-17:00 由上交所主办的 2025 年半年度科创板医疗器械及医疗设备行业集体业 绩说明会，此次活动将采用网络文字互动的方式举行，投资者可登录上海证券交易 所上证路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、 说明会类型 投资者可于 2025 年 09 月 10 日（星期三）至 09 月 16 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investor@ succeeder.com.cn 将需要了解和关注的问题提前提供给公司。公司将在说明会上 对投资者普遍关注的问题进行回答。 证券代码：688338 证券简称：赛科希德 公告编号：2025-041 北京赛科希德科技 ...

Core Viewpoint - The financial performance of Saikohide (688338) for the first half of 2025 shows a significant decline in revenue and net profit compared to the previous year, indicating challenges in the market and increased operational costs [1] Financial Performance Summary - Total revenue for the first half of 2025 was 139 million yuan, a decrease of 12.62% year-on-year [1] - Net profit attributable to shareholders was 47.99 million yuan, down 23.47% year-on-year [1] - Gross margin was 62.13%, a decrease of 1.37 percentage points year-on-year, while net margin was 34.51%, down 12.47 percentage points [1] - Total expenses (selling, administrative, and financial) accounted for 15.42% of total revenue, an increase of 47.39% year-on-year [1] - Earnings per share decreased to 0.46 yuan, down 22.03% year-on-year [1] Cash Flow and Asset Management - Cash flow from operating activities decreased by 28.55%, attributed to reduced sales revenue and slower collection of receivables [5] - The company increased its investment in structured deposits, leading to a 29.33% decrease in cash and cash equivalents [3] - The company reported a 150.08% increase in trading financial assets due to the same investment strategy [3] Revenue and Cost Analysis - Revenue decline of 12.62% was influenced by stricter management of inspection projects by medical institutions and reduced sales of reagents and consumables [5] - Operating costs also decreased by 10.57%, reflecting the overall drop in revenue [5] Debt and Liabilities - The company’s interest-bearing liabilities decreased by 14.87% [1] - Employee compensation liabilities decreased by 43.35% due to the payment of annual bonuses [4] Investment and Return Metrics - The company's return on invested capital (ROIC) was 5.49%, indicating average capital returns [8] - Historical data shows a median ROIC of 6.48% since the company’s listing, with the lowest recorded ROIC at 4.98% in 2021 [8] Overall Financial Health - The company maintains a healthy cash asset position, indicating good liquidity despite the decline in revenue and profit [9]

Core Viewpoint - The company plans to utilize idle self-owned funds for cash management, aiming to enhance the efficiency of fund usage and increase returns for shareholders while ensuring the safety of funds and normal business operations [4][58]. Group 1: Cash Management Overview - The company intends to use up to RMB 105,000 million of idle self-owned funds for cash management, focusing on high-security, liquid, and principal-protected cash management products [4][8]. - The cash management authorization period is set for 12 months from the board's approval date, allowing for rolling use of funds within the specified limit [4][54]. - The purpose of cash management is to improve the efficiency of idle funds and increase returns for the company and its shareholders [4][52]. Group 2: Financial Data and Fund Management - The company raised a total of RMB 102,774.42 million from its initial public offering, with a net amount of RMB 92,426.96 million after deducting issuance costs [50]. - All raised funds are managed in a dedicated account, and the company has established relevant regulatory agreements to ensure proper management and usage of the funds [19][50]. - As of June 30, 2025, the company has not used idle raised funds to supplement working capital [26]. Group 3: Risk Management and Control Measures - The company will select cash management products that are high in security and liquidity, with a maximum term of 12 months, and will not engage in non-principal-protected products [6][59]. - The finance department will monitor the operation and progress of cash management products, taking timely measures to mitigate risks if adverse factors are identified [11][60]. - The board's audit committee and independent directors have the authority to supervise and inspect the use of raised funds and cash management activities [11][60]. Group 4: Approval and Compliance - The board of directors and the supervisory board approved the cash management proposal during meetings held on August 20, 2025 [62][68]. - The proposal complies with relevant laws and regulations, ensuring that it does not affect the normal operation of fundraising investment projects or harm the interests of shareholders [63][65].

Group 1 - The company announced the convening of the third meeting of the fourth board of directors and the third meeting of the fourth supervisory board on August 20, 2025 [2] - The company approved a proposal to use temporarily idle raised funds for cash management, with a limit not exceeding RMB 155 million [2] - The cash management will involve purchasing safe and liquid principal-protected financial products, ensuring that it does not affect the construction of investment projects and normal operations [2]

Core Points - The company announced a plan to use idle self-owned funds for cash management, with a maximum amount of RMB 105,000.00 million [1] - The cash management products to be purchased will be high-security, good liquidity, and capital-preserving [1] - The authorization period for this plan is 12 months from the date of the board's approval, allowing for rolling use of funds within the specified limit [1]

Group 1 - The core point of the article is that Saikohide announced the approval of several proposals during the third meeting of its fourth supervisory board [2] Group 2 - The announcement was made on the evening of August 21 [2] - The proposals included the agenda and summary of the meeting [2]

证券日报网讯 8月21日晚间，赛科希德发布公告称，公司第四届董事会第三次会议审议通过了《关于及 摘要的议案》等多项议案。 （文章来源：证券日报） ...

Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company achieved operating revenue of 139 million yuan, representing a year-on-year decrease of 12.62% [1] - The net profit attributable to shareholders was 47.9999 million yuan, down 23.47% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 46.2395 million yuan, reflecting a year-on-year decline of 25.74% [1] - Basic earnings per share were reported at 0.46 yuan [1]

Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of 2025, primarily due to the impact of medical insurance cost control policies on the demand in the in vitro diagnostic industry [1] Financial Performance - The company achieved an operating revenue of 139 million yuan, representing a year-on-year decrease of 12.62% [1] - The net profit attributable to the parent company was 47.9999 million yuan, down 23.47% year-on-year [1] - The basic earnings per share stood at 0.46 yuan [1] Industry Impact - The decline in revenue is attributed to the effects of medical insurance cost control policies on the demand within the in vitro diagnostic sector [1]